CA3187578A1 - Methode de traitement de sous-types de lma a l'aide d'agents de depletion de l'arginine - Google Patents
Methode de traitement de sous-types de lma a l'aide d'agents de depletion de l'arginineInfo
- Publication number
- CA3187578A1 CA3187578A1 CA3187578A CA3187578A CA3187578A1 CA 3187578 A1 CA3187578 A1 CA 3187578A1 CA 3187578 A CA3187578 A CA 3187578A CA 3187578 A CA3187578 A CA 3187578A CA 3187578 A1 CA3187578 A1 CA 3187578A1
- Authority
- CA
- Canada
- Prior art keywords
- arginine
- depleting agent
- leukemia
- acute
- aml
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 52
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 136
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract description 122
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 95
- 238000011282 treatment Methods 0.000 claims abstract description 65
- 208000026784 acute myeloblastic leukemia with maturation Diseases 0.000 claims abstract description 20
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims abstract description 16
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims abstract description 15
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims abstract description 14
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims abstract description 12
- 208000021841 acute erythroid leukemia Diseases 0.000 claims abstract description 9
- 206010014950 Eosinophilia Diseases 0.000 claims abstract description 8
- 208000036566 Erythroleukaemia Diseases 0.000 claims abstract description 8
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims abstract description 8
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims abstract description 8
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims abstract description 8
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims abstract description 8
- 239000004475 Arginine Substances 0.000 claims description 49
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 49
- 102000004190 Enzymes Human genes 0.000 claims description 35
- 108090000790 Enzymes Proteins 0.000 claims description 35
- 241000282414 Homo sapiens Species 0.000 claims description 34
- 102000004452 Arginase Human genes 0.000 claims description 29
- 108700024123 Arginases Proteins 0.000 claims description 29
- 230000001925 catabolic effect Effects 0.000 claims description 22
- 239000002202 Polyethylene glycol Substances 0.000 claims description 16
- 150000001413 amino acids Chemical group 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- 102000009027 Albumins Human genes 0.000 claims description 14
- 108010088751 Albumins Proteins 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108010082340 Arginine deiminase Proteins 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102100032252 Antizyme inhibitor 2 Human genes 0.000 claims description 8
- 101000798222 Homo sapiens Antizyme inhibitor 2 Proteins 0.000 claims description 7
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 7
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 7
- 108010004429 arginine 2-monooxygenase Proteins 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 102000007562 Serum Albumin Human genes 0.000 claims description 5
- 108010071390 Serum Albumin Proteins 0.000 claims description 5
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims description 4
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 4
- 230000035800 maturation Effects 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 25
- 206010028980 Neoplasm Diseases 0.000 description 59
- 241000699670 Mus sp. Species 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 35
- 229940088598 enzyme Drugs 0.000 description 31
- 102000053640 Argininosuccinate synthases Human genes 0.000 description 22
- 108700024106 Argininosuccinate synthases Proteins 0.000 description 22
- 230000001093 anti-cancer Effects 0.000 description 21
- 238000011269 treatment regimen Methods 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- 230000002950 deficient Effects 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 230000009467 reduction Effects 0.000 description 9
- 241001529936 Murinae Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000004900 autophagic degradation Effects 0.000 description 5
- 230000002886 autophagic effect Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 5
- 208000035330 Acute monoblastic/monocytic leukemia Diseases 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000784014 Homo sapiens Argininosuccinate synthase Proteins 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000002784 cytotoxicity assay Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000006320 pegylation Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- 101710186578 Arginase-2, mitochondrial Proteins 0.000 description 3
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000000719 anti-leukaemic effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000029918 bioluminescence Effects 0.000 description 3
- 238000005415 bioluminescence Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- 235000013477 citrulline Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000013105 post hoc analysis Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000193755 Bacillus cereus Species 0.000 description 2
- 102000004072 Beclin-1 Human genes 0.000 description 2
- 108090000524 Beclin-1 Proteins 0.000 description 2
- 241000589968 Borrelia Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 102000004039 Caspase-9 Human genes 0.000 description 2
- 108090000566 Caspase-9 Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000700131 Heterocephalus glaber Species 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 241000193390 Parageobacillus thermoglucosidasius Species 0.000 description 2
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 241000607265 Vibrio vulnificus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 230000009789 autophagic cell death Effects 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- ASUGWWOMVNVWAW-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrrole-2,5-dione Chemical compound COCCN1C(=O)C=CC1=O ASUGWWOMVNVWAW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
- 241000589159 Agrobacterium sp. Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 241001468259 Anoxybacillus flavithermus Species 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 108700016156 Arginine decarboxylases Proteins 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 101000792852 Bacillus caldovelox Arginase Proteins 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241000193398 Bacillus methanolicus Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101000792834 Bos taurus Arginase-2, mitochondrial Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000193417 Brevibacillus laterosporus Species 0.000 description 1
- 241000186309 Brevibacterium helvolum Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283705 Capra hircus Species 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000286316 Desmospora Species 0.000 description 1
- 241000186539 Desulfotomaculum ruminis Species 0.000 description 1
- 101100323155 Dictyostelium discoideum snfA gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000193419 Geobacillus kaustophilus Species 0.000 description 1
- 241001468175 Geobacillus thermodenitrificans Species 0.000 description 1
- 241001468176 Geobacillus thermoleovorans Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000546751 Halopiger xanaduensis Species 0.000 description 1
- 241001462428 Helicobacter cinaedi CCUG 18818 = ATCC BAA-847 Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000382840 Hyriopsis cumingii Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000203407 Methanocaldococcus jannaschii Species 0.000 description 1
- 241000719288 Methylobacter tundripaludum Species 0.000 description 1
- 241001508001 Microbacterium laevaniformans Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000792836 Mus musculus Arginase-2, mitochondrial Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204048 Mycoplasma hominis Species 0.000 description 1
- 241000736806 Natrialba magadii Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241000522557 Octadecabacter arcticus Species 0.000 description 1
- 241000277275 Oncorhynchus mykiss Species 0.000 description 1
- 101000792837 Oryctolagus cuniculus Arginase-2, mitochondrial Proteins 0.000 description 1
- 241000277347 Osmerus mordax Species 0.000 description 1
- 241000884012 Paenibacillus dendritiformis Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000701245 Paramecium bursaria Chlorella virus 1 Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000203720 Pimelobacter simplex Species 0.000 description 1
- 241001001977 Planococcus donghaensis Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000861914 Plecoglossus altivelis Species 0.000 description 1
- 241000770209 Porphyromonas uenonis Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241001223182 Pseudomonas plecoglossicida Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101000792838 Rattus norvegicus Arginase-2, mitochondrial Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000516658 Roseiflexus castenholzii Species 0.000 description 1
- 241000277289 Salmo salar Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000983364 Stenotrophomonas sp. Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000205091 Sulfolobus solfataricus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000204652 Thermotoga Species 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 241000088680 Thermus islandicus Species 0.000 description 1
- 241000815432 Thermus parvatiensis Species 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 241001618048 halophilic archaeon DL31 Species 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N propionic aldehyde Natural products CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Selon l'invention, une méthode de traitement de la leucémie myéloïde aiguë (LMA) chez un sujet qui en a besoin comprend l'administration d'une quantité thérapeutiquement efficace d'un agent de déplétion de l'arginine au sujet, la LMA étant du sous-type M0 (leucémie myéloblastique aigüe sans différenciation), M2 (leucémie myéloblastique aigüe avec maturation), M4 (leucémie myéloblastique aigüe avec maturation), M4 eos (leucémie myélomonocytique aigüe avec éosinophilie), M5 (leucémie monocytique aigüe), M6 (leucémie érythroïde aigüe) ou M7 (leucémie mégakaryoblastique aigüe) du système franco-américano-britannique (FAB). L'invention concerne également un médicament comportant un agent de déplétion de l'arginine pour traiter la LMA chez un sujet qui en a besoin, la LMA étant du sous-type M0 (leucémie myéloblastique aigüe sans différenciation), M2 (leucémie myéloblastique aigüe avec maturation), M4 (leucémie myéloblastique aigüe avec maturation), M4 eos (leucémie myélomonocytique aigüe avec éosinophilie), M5 (leucémie monocytique aigüe), M6 (leucémie érythroïde aigüe) ou M7 (leucémie mégakaryoblastique aigüe) du système franco-américano-britannique (FAB).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/098681 WO2022000151A1 (fr) | 2020-06-29 | 2020-06-29 | Méthode de traitement de sous-types de lma à l'aide d'agents de déplétion de l'arginine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3187578A1 true CA3187578A1 (fr) | 2022-01-06 |
Family
ID=79317763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3187578A Pending CA3187578A1 (fr) | 2020-06-29 | 2020-06-29 | Methode de traitement de sous-types de lma a l'aide d'agents de depletion de l'arginine |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4153167A4 (fr) |
| KR (1) | KR20230104110A (fr) |
| CN (1) | CN115697320A (fr) |
| CA (1) | CA3187578A1 (fr) |
| TW (1) | TW202206095A (fr) |
| WO (1) | WO2022000151A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4069280A4 (fr) * | 2019-12-02 | 2024-01-03 | The Hong Kong Polytechnic University | Procédés pour induire un jeûne intermittent et moduler l'autophagie |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006015512A1 (fr) * | 2004-08-11 | 2006-02-16 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Arginine déiminase modifiée |
| TWI577386B (zh) * | 2012-04-04 | 2017-04-11 | 普拉瑞斯集團 | 利用精胺酸去亞胺酶之治療方法 |
| US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
| TW202440153A (zh) * | 2016-07-05 | 2024-10-16 | 開曼群島商北極星藥業集團股份有限公司 | 用精胺酸耗盡劑進行之組合癌症免疫療法 |
| WO2018058125A1 (fr) * | 2016-09-26 | 2018-03-29 | Ensemble Group Holdings | Procédés d'évaluation et de traitement du cancer chez des sujets ayant des systèmes lymphatiques dysrégulés |
-
2020
- 2020-06-29 CA CA3187578A patent/CA3187578A1/fr active Pending
- 2020-06-29 KR KR1020237003309A patent/KR20230104110A/ko active Pending
- 2020-06-29 EP EP20943510.6A patent/EP4153167A4/fr not_active Withdrawn
- 2020-06-29 CN CN202080101412.8A patent/CN115697320A/zh active Pending
- 2020-06-29 WO PCT/CN2020/098681 patent/WO2022000151A1/fr not_active Ceased
-
2021
- 2021-02-19 TW TW110105746A patent/TW202206095A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230104110A (ko) | 2023-07-07 |
| EP4153167A4 (fr) | 2024-02-28 |
| WO2022000151A1 (fr) | 2022-01-06 |
| EP4153167A1 (fr) | 2023-03-29 |
| CN115697320A (zh) | 2023-02-03 |
| TW202206095A (zh) | 2022-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patel et al. | Current advances in the treatment of BRAF-mutant melanoma | |
| Lee et al. | Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis | |
| JP2011526626A5 (fr) | ||
| JP2008502738A (ja) | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 | |
| US12145007B2 (en) | Dual cytokine fusion proteins comprising IL-10 | |
| JP7080053B2 (ja) | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 | |
| JP7373998B2 (ja) | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 | |
| JP2012504423A (ja) | 治療用リボヌクレアーゼ | |
| US20230287075A1 (en) | Dual cytokine fusion proteins comprising multi-subunit cytokines | |
| EP3448363A1 (fr) | Nouvelle composition pharmaceutique comprenant des particules comprenant un complexe constitué d'un polyribonucléotide double brin et d'une polyalkylène imine | |
| WO2019213686A1 (fr) | Compositions thérapeutiques et leurs utilisations | |
| WO2015138638A1 (fr) | Agonistes de récepteur de protéine trail à action prolongée pour le traitement de maladies auto-immunes | |
| Ward et al. | Clinical experience of cancer immunotherapy integrated with oleic acid complexed with de-glycosylated vitamin D binding protein | |
| US20210401952A1 (en) | Method of treating AML subtypes using arginine-depleting agents | |
| TW201113372A (en) | Tumoricidal, bactericidal, or viricidal macrophage activation | |
| WO2022000151A1 (fr) | Méthode de traitement de sous-types de lma à l'aide d'agents de déplétion de l'arginine | |
| Farasati Far et al. | Fundamental concepts of protein therapeutics and spacing in oncology: an updated comprehensive review | |
| US20240075161A1 (en) | Engineered exosomes to detect and deplete pro-tumorigenic macrophages | |
| CN118715239A (zh) | 包含多亚基细胞因子的双细胞因子融合蛋白 | |
| EP3142692B1 (fr) | Compositions contenant l'il-31 et leurs utilisations | |
| US20230233705A1 (en) | Gold nanoparticle-containing medicine | |
| JP2022513403A (ja) | ジフテリア毒素－ヒトインターロイキン－３結合体と他の薬剤との組合せにより骨髄増殖性腫瘍を治療する併用療法の方法 | |
| TWI676683B (zh) | 用於癌症治療之對ａｄｉ－ｐｅｇ２０抗體交叉反應性降低之精胺酸去亞胺酶 | |
| US10874711B2 (en) | Use of annexin V to reduce the spread of intracellular pathogens | |
| KR20180129585A (ko) | Mage-1에 특이적으로 결합하는 압타머 및 이의 용도 |